𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma

✍ Scribed by Eric J. Small; John W. Frye; Mary J. Wilkinson; Peter R. Carroll; Mary Lou Ernest; Robert J. Stagg

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
507 KB
Volume
73
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase II study of constant-infusion fl
A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma
✍ Mary J. Wilkinson; John W. Frye; Eric J. Small; Alan P. Venook; Peter R. Carroll πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 347 KB πŸ‘ 2 views

Background. Twenty-nine patients with metastatic renal cell carcinoma (RCC) were treated with constantinfusion floxuridine (FUdR, Roche Laboratories, Nut-Methods. The initial dosage was 0.075 mg/kg/day for 14 days every 28 days and was increased or decreased by 0.025-mg/kg/day increments at each sub

A high rate of venous thromboembolism in
A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma
✍ Apurva A. Desai; Nicholas J. Vogelzang; Brian I. Rini; Rafat Ansari; Stuart Krau πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 87 KB πŸ‘ 2 views

## Abstract ## BACKGROUND The objective of this study was to determine the clinical response rate of the combination of weekly intravenous (IV) gemcitabine with continuous infusion fluorouracil (5‐FU) and daily oral thalidomide in patients with metastatic renal cell carcinoma (RCC). ## METHODS B